Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 4/20 | 0.38 |
| ▸ | CHUK | O15111 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 3/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.37 |
| ▸ | EZH2 | Q15910 | 5/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034242 | 0.81 | HSP90AA1 (0.45) | HRH3KCNH2USP2TSHRHIF1A | |
| SCHEMBL13848733 | 0.80 | TP53 (0.39) | MAPK14 | |
| SCHEMBL4033413 | 0.79 | ABL1 (0.54) | HRH3ABL1BCR | |
| SCHEMBL13843810 | 0.78 | NAPRT (0.43) | — | |
| SCHEMBL13895052 | 0.74 | TP53 (0.32) | ABL1BCR | |
| SCHEMBL13848653 | 0.73 | KMO (0.48) | ABL1BCR | |
| SCHEMBL2305325 | 0.73 | HRH3 (0.62) | HRH3HIF1AEPAS1 | |
| SCHEMBL17075537 | 0.72 | HRH3 (0.61) | HRH3HIF1AEPAS1 | |
| SCHEMBL30911745 | 0.69 | HRH3 (0.66) | HRH3HIF1AEPAS1 | |
| SCHEMBL13848887 | 0.68 | MKNK1 (0.44) | ABL1BCRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725544-B1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7514458-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1887003-A1 | 3-[4-HETEROCYCLYL -1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | COGAN DEREK | 2007-06-21 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | TNF, IL6, IL1A | HRH3 340/4885KCNH2 4068/4885USP2 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.